Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K.

Haematologica. 2016 Dec;101(12):1451-1459. Epub 2016 Nov 10. Review.

2.

Multiple myeloma cancer stem cells.

Gao M, Kong Y, Yang G, Gao L, Shi J.

Oncotarget. 2016 Jun 7;7(23):35466-77. doi: 10.18632/oncotarget.8154. Review.

3.

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades C, Viselli S, Neuwirth R, Esseltine DL, Anderson K, Ghobrial IM, San Miguel JF, Richardson PG, Tomasson MH, Michor F.

Clin Cancer Res. 2016 Aug 15;22(16):4206-4214. doi: 10.1158/1078-0432.CCR-15-2793. Epub 2016 Mar 22.

PMID:
27006493
4.

Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.

Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S.

BMC Cancer. 2015 Nov 6;15:864. doi: 10.1186/s12885-015-1892-7.

5.

Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods.

Evans HR, Karmakharm T, Lawson MA, Walker RE, Harris W, Fellows C, Huggins ID, Richmond P, Chantry AD.

Bone. 2016 Feb;83:9-16. doi: 10.1016/j.bone.2015.10.004. Epub 2015 Oct 8.

6.

The use of MAGE C1 and flow cytometry to determine the malignant cell type in multiple myeloma.

Wienand K, Shires K.

PLoS One. 2015 Mar 20;10(3):e0120734. doi: 10.1371/journal.pone.0120734. eCollection 2015.

7.

Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.

Zou J, Chen D, Zong Y, Ye S, Tang J, Meng H, An G, Zhang X, Yang L.

Cancer Sci. 2015 May;106(5):512-21. doi: 10.1111/cas.12631. Epub 2015 Mar 13.

8.

Immunological dysregulation in multiple myeloma microenvironment.

Romano A, Conticello C, Cavalli M, Vetro C, La Fauci A, Parrinello NL, Di Raimondo F.

Biomed Res Int. 2014;2014:198539. doi: 10.1155/2014/198539. Epub 2014 Jun 11. Review.

9.

High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.

Wen J, Li H, Tao W, Savoldo B, Foglesong JA, King LC, Zu Y, Chang CC.

Br J Haematol. 2014 Sep;166(5):711-9. doi: 10.1111/bjh.12951. Epub 2014 May 29.

10.

N-cadherin impedes proliferation of the multiple myeloma cancer stem cells.

Sadler NM, Harris BR, Metzger BA, Kirshner J.

Am J Blood Res. 2013 Dec 18;3(4):271-85. eCollection 2013.

11.

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.

Tanno T, Lim Y, Wang Q, Chesi M, Bergsagel PL, Matthews G, Johnstone RW, Ghosh N, Borrello I, Huff CA, Matsui W.

Blood. 2014 Jan 30;123(5):725-33. doi: 10.1182/blood-2013-08-524025. Epub 2013 Dec 17.

12.

Fact or fiction--identifying the elusive multiple myeloma stem cell.

Kellner J, Liu B, Kang Y, Li Z.

J Hematol Oncol. 2013 Dec 7;6:91. doi: 10.1186/1756-8722-6-91. Review.

13.

Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.

Schueler J, Wider D, Klingner K, Siegers GM, May AM, Wäsch R, Fiebig HH, Engelhardt M.

PLoS One. 2013 Nov 6;8(11):e79939. doi: 10.1371/journal.pone.0079939. eCollection 2013.

14.

Cancer stem cells of differentiated B-cell malignancies: models and consequences.

Gross E, Quillet-Mary A, Ysebaert L, Laurent G, Fournie JJ.

Cancers (Basel). 2011 Mar 25;3(2):1566-79. doi: 10.3390/cancers3021566.

15.

Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance.

Thiago LS, Perez-Andres M, Balanzategui A, Sarasquete ME, Paiva B, Jara-Acevedo M, Barcena P, Sanchez ML, Almeida J, González M, San Miguel JF, Garcia-Sanz R, Orfao A.

Haematologica. 2014 Jan;99(1):155-62. doi: 10.3324/haematol.2013.092817. Epub 2013 Jul 19.

16.

NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.

Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S.

Exp Hematol. 2013 Jun;41(6):547-557.e2. doi: 10.1016/j.exphem.2013.02.008. Epub 2013 Feb 19.

17.

Stemness of B-cell progenitors in multiple myeloma bone marrow.

Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE.

Clin Cancer Res. 2012 Nov 15;18(22):6155-68. doi: 10.1158/1078-0432.CCR-12-0531. Epub 2012 Sep 17.

18.

Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.

Li X, Ling W, Khan S, Yaccoby S.

J Bone Miner Res. 2012 Aug;27(8):1635-48. doi: 10.1002/jbmr.1620.

19.

Progress in myeloma stem cells.

Cruz RD, Tricot G, Zangari M, Zhan F.

Am J Blood Res. 2011;1(2):135-45. Epub 2011 Sep 8.

20.

Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma.

Trepel M, Martens V, Doll C, Rahlff J, Gösch B, Loges S, Binder M.

PLoS One. 2012;7(2):e31998. doi: 10.1371/journal.pone.0031998. Epub 2012 Feb 22.

Supplemental Content

Support Center